Value of quantitative FDG PET/CT volumetric biomarkers in recurrent colorectal cancer patient survival

Charles Marcus, Rick Wray, Mehdi Taghipour, Wael Marashdeh, Se Jin Ahn, Esther Mena, Rathan M. Subramaniam

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE. The purpose of this study was to evaluate the impact of quantitative PET parameters in the overall survival of patients with recurrent colorectal cancer. MATERIALS AND METHODS. A total of 105 patients with a biopsy-proven recurrence of colorectal cancer who underwent PET/CT were included in the study. A gradient segmentation method was used to calculate maximum and peak standardized uptake values (SUVmax, SUVpeak), total lesion glycolysis (TLGtotal), and metabolic tumor volume (MTVt otal). These parameters were measured for each recurrent lesion at the primary, locoregional, and distant sites. The median follow-up time was 31.3 months. Overall survival (OS) was the primary outcome and was calculated using Kaplan-Meier survival plots and Cox regression analyses. RESULTS. The mean ± SD for SUVmax, SUVpeak, TLGtotal, and MTVtotal of the included patients was 7.3 ± 5.3, 5.3 ± 3.3, 280.8 ± 1181 g, and 79.8 ± 294 mL, respectively. The median OS for patients who were alive was 50 months in comparison with 23.4 months among patients who died. Age (p = 0.041), tumor grade (p = 0.010), median TLG (p = 0.031), and median MTV (p = 0.009) remained significantly associated with OS in the multivariate Cox regression analysis. Kaplan-Meier survival analysis performed on the basis of the median PET/CT parametric values showed that SUVmax (threshold, 5.63; hazard ratio [HR] = 1.7; 95% CI, 1-2.8; p = 0.02), MTVtotal (threshold, 13.85 mL; HR = 2.2; 95% CI, 1.3-3.9; p = 0.003), and TLGtotal (threshold, 36.14 g; HR = 1.9; 95% CI, 1.1-3.3; p = 0.01) were significant predictors of OS during follow-up. An integrated risk stratification model with SUVmax and MTVtotal into three subgroups predicted patient survival outcomes (HR = 1.8; 95% CI, 1.25-2.65; logrank p = 0.003). CONCLUSION. SUVmax, MTVtotal, TLGtotal, and integrated score with FDG avidity and total tumor burden provide survival information for patients with biopsy-proven recurrent colorectal cancer.

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalAmerican Journal of Roentgenology
Volume207
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Cone-Beam Computed Tomography
Colorectal Neoplasms
Biomarkers
Survival
Tumor Burden
Regression Analysis
Biopsy
Kaplan-Meier Estimate
Glycolysis
Survival Analysis
Recurrence

Keywords

  • Colorectal cancer
  • Follow-up
  • Metabolic tumor volume
  • Overall survival
  • PET/CT
  • Recurrence
  • Standardized uptake value
  • Total lesion glycolysis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Value of quantitative FDG PET/CT volumetric biomarkers in recurrent colorectal cancer patient survival. / Marcus, Charles; Wray, Rick; Taghipour, Mehdi; Marashdeh, Wael; Ahn, Se Jin; Mena, Esther; Subramaniam, Rathan M.

In: American Journal of Roentgenology, Vol. 207, No. 2, 01.08.2016, p. 257-265.

Research output: Contribution to journalArticle

Marcus, Charles ; Wray, Rick ; Taghipour, Mehdi ; Marashdeh, Wael ; Ahn, Se Jin ; Mena, Esther ; Subramaniam, Rathan M. / Value of quantitative FDG PET/CT volumetric biomarkers in recurrent colorectal cancer patient survival. In: American Journal of Roentgenology. 2016 ; Vol. 207, No. 2. pp. 257-265.
@article{2e88345bffe84bbba597b8e0e6ca8549,
title = "Value of quantitative FDG PET/CT volumetric biomarkers in recurrent colorectal cancer patient survival",
abstract = "OBJECTIVE. The purpose of this study was to evaluate the impact of quantitative PET parameters in the overall survival of patients with recurrent colorectal cancer. MATERIALS AND METHODS. A total of 105 patients with a biopsy-proven recurrence of colorectal cancer who underwent PET/CT were included in the study. A gradient segmentation method was used to calculate maximum and peak standardized uptake values (SUVmax, SUVpeak), total lesion glycolysis (TLGtotal), and metabolic tumor volume (MTVt otal). These parameters were measured for each recurrent lesion at the primary, locoregional, and distant sites. The median follow-up time was 31.3 months. Overall survival (OS) was the primary outcome and was calculated using Kaplan-Meier survival plots and Cox regression analyses. RESULTS. The mean ± SD for SUVmax, SUVpeak, TLGtotal, and MTVtotal of the included patients was 7.3 ± 5.3, 5.3 ± 3.3, 280.8 ± 1181 g, and 79.8 ± 294 mL, respectively. The median OS for patients who were alive was 50 months in comparison with 23.4 months among patients who died. Age (p = 0.041), tumor grade (p = 0.010), median TLG (p = 0.031), and median MTV (p = 0.009) remained significantly associated with OS in the multivariate Cox regression analysis. Kaplan-Meier survival analysis performed on the basis of the median PET/CT parametric values showed that SUVmax (threshold, 5.63; hazard ratio [HR] = 1.7; 95{\%} CI, 1-2.8; p = 0.02), MTVtotal (threshold, 13.85 mL; HR = 2.2; 95{\%} CI, 1.3-3.9; p = 0.003), and TLGtotal (threshold, 36.14 g; HR = 1.9; 95{\%} CI, 1.1-3.3; p = 0.01) were significant predictors of OS during follow-up. An integrated risk stratification model with SUVmax and MTVtotal into three subgroups predicted patient survival outcomes (HR = 1.8; 95{\%} CI, 1.25-2.65; logrank p = 0.003). CONCLUSION. SUVmax, MTVtotal, TLGtotal, and integrated score with FDG avidity and total tumor burden provide survival information for patients with biopsy-proven recurrent colorectal cancer.",
keywords = "Colorectal cancer, Follow-up, Metabolic tumor volume, Overall survival, PET/CT, Recurrence, Standardized uptake value, Total lesion glycolysis",
author = "Charles Marcus and Rick Wray and Mehdi Taghipour and Wael Marashdeh and Ahn, {Se Jin} and Esther Mena and Subramaniam, {Rathan M.}",
year = "2016",
month = "8",
day = "1",
doi = "10.2214/AJR.15.15806",
language = "English (US)",
volume = "207",
pages = "257--265",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - Value of quantitative FDG PET/CT volumetric biomarkers in recurrent colorectal cancer patient survival

AU - Marcus, Charles

AU - Wray, Rick

AU - Taghipour, Mehdi

AU - Marashdeh, Wael

AU - Ahn, Se Jin

AU - Mena, Esther

AU - Subramaniam, Rathan M.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - OBJECTIVE. The purpose of this study was to evaluate the impact of quantitative PET parameters in the overall survival of patients with recurrent colorectal cancer. MATERIALS AND METHODS. A total of 105 patients with a biopsy-proven recurrence of colorectal cancer who underwent PET/CT were included in the study. A gradient segmentation method was used to calculate maximum and peak standardized uptake values (SUVmax, SUVpeak), total lesion glycolysis (TLGtotal), and metabolic tumor volume (MTVt otal). These parameters were measured for each recurrent lesion at the primary, locoregional, and distant sites. The median follow-up time was 31.3 months. Overall survival (OS) was the primary outcome and was calculated using Kaplan-Meier survival plots and Cox regression analyses. RESULTS. The mean ± SD for SUVmax, SUVpeak, TLGtotal, and MTVtotal of the included patients was 7.3 ± 5.3, 5.3 ± 3.3, 280.8 ± 1181 g, and 79.8 ± 294 mL, respectively. The median OS for patients who were alive was 50 months in comparison with 23.4 months among patients who died. Age (p = 0.041), tumor grade (p = 0.010), median TLG (p = 0.031), and median MTV (p = 0.009) remained significantly associated with OS in the multivariate Cox regression analysis. Kaplan-Meier survival analysis performed on the basis of the median PET/CT parametric values showed that SUVmax (threshold, 5.63; hazard ratio [HR] = 1.7; 95% CI, 1-2.8; p = 0.02), MTVtotal (threshold, 13.85 mL; HR = 2.2; 95% CI, 1.3-3.9; p = 0.003), and TLGtotal (threshold, 36.14 g; HR = 1.9; 95% CI, 1.1-3.3; p = 0.01) were significant predictors of OS during follow-up. An integrated risk stratification model with SUVmax and MTVtotal into three subgroups predicted patient survival outcomes (HR = 1.8; 95% CI, 1.25-2.65; logrank p = 0.003). CONCLUSION. SUVmax, MTVtotal, TLGtotal, and integrated score with FDG avidity and total tumor burden provide survival information for patients with biopsy-proven recurrent colorectal cancer.

AB - OBJECTIVE. The purpose of this study was to evaluate the impact of quantitative PET parameters in the overall survival of patients with recurrent colorectal cancer. MATERIALS AND METHODS. A total of 105 patients with a biopsy-proven recurrence of colorectal cancer who underwent PET/CT were included in the study. A gradient segmentation method was used to calculate maximum and peak standardized uptake values (SUVmax, SUVpeak), total lesion glycolysis (TLGtotal), and metabolic tumor volume (MTVt otal). These parameters were measured for each recurrent lesion at the primary, locoregional, and distant sites. The median follow-up time was 31.3 months. Overall survival (OS) was the primary outcome and was calculated using Kaplan-Meier survival plots and Cox regression analyses. RESULTS. The mean ± SD for SUVmax, SUVpeak, TLGtotal, and MTVtotal of the included patients was 7.3 ± 5.3, 5.3 ± 3.3, 280.8 ± 1181 g, and 79.8 ± 294 mL, respectively. The median OS for patients who were alive was 50 months in comparison with 23.4 months among patients who died. Age (p = 0.041), tumor grade (p = 0.010), median TLG (p = 0.031), and median MTV (p = 0.009) remained significantly associated with OS in the multivariate Cox regression analysis. Kaplan-Meier survival analysis performed on the basis of the median PET/CT parametric values showed that SUVmax (threshold, 5.63; hazard ratio [HR] = 1.7; 95% CI, 1-2.8; p = 0.02), MTVtotal (threshold, 13.85 mL; HR = 2.2; 95% CI, 1.3-3.9; p = 0.003), and TLGtotal (threshold, 36.14 g; HR = 1.9; 95% CI, 1.1-3.3; p = 0.01) were significant predictors of OS during follow-up. An integrated risk stratification model with SUVmax and MTVtotal into three subgroups predicted patient survival outcomes (HR = 1.8; 95% CI, 1.25-2.65; logrank p = 0.003). CONCLUSION. SUVmax, MTVtotal, TLGtotal, and integrated score with FDG avidity and total tumor burden provide survival information for patients with biopsy-proven recurrent colorectal cancer.

KW - Colorectal cancer

KW - Follow-up

KW - Metabolic tumor volume

KW - Overall survival

KW - PET/CT

KW - Recurrence

KW - Standardized uptake value

KW - Total lesion glycolysis

UR - http://www.scopus.com/inward/record.url?scp=84979518407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979518407&partnerID=8YFLogxK

U2 - 10.2214/AJR.15.15806

DO - 10.2214/AJR.15.15806

M3 - Article

C2 - 27447341

AN - SCOPUS:84979518407

VL - 207

SP - 257

EP - 265

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -